Regeneron Pharmaceuticals REGN

Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development and production of innovative medical treatments. The company was founded in 1988 in New York.

Regeneron Pharmaceuticals' main areas of focus are research and development of drugs for the treatment of various diseases, including oncological, autoimmune, infectious, and others.

One of the company's most well-known products is Eylea, which is used to treat age-related macular degeneration. In addition, Regeneron Pharmaceuticals is developing drugs for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and other conditions.

The company invests heavily in scientific research and development to create innovative and effective drugs. Regeneron Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.

Regeneron Pharmaceuticals has a wide network of distributors and partners around the world, enabling it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.